 |
Vol.59 No.3 contents | Japanese/English |
 | Full Text of PDF (818K) Article in Japanese |
- Case Report -
Treatment of ALK-positive Lung Cancer with Crizotinib-derived Complexed Renal Cysts Using Alectinib and Ceritinib: a Case Study
Kosuke Hamai1, Seika Tamamoto1, Ayako Nishida1, Takuya Tanimoto1, Hiroyasu Shoda1, Nobuhisa Ishikawa11Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan
Background. The antitumor effect of crizotinib is mediated through the inhibition of anaplastic lymphoma kinase (ALK), c-MET and ROS1. However, crizotinib treatment is associated with several adverse events that occur due to the same mechanism. Case. A 67-year-old woman presented with cough, and lung cancer was suspected after chest computed tomography. She was diagnosed with lung adenocarcinoma harboring ALK-rearrangement by bronchoscopy and was treated with crizotinib. Thereafter, crizotinib treatment was stopped due to development of tyrosine kinase inhibitor-derived complexed renal cysts. She received alectinib as a fourth line treatment, and ceritinib as a sixth line treatment, after cytotoxic chemotherapy; however, there was no recurrence of the complexed renal cysts. Conclusion. We reported a case in which a patient with ALK-positive lung adenocarcinoma with crizotinib-derived complexed renal cysts was treated with alectinib and ceritinib.
key words: ALK-positive lung cancer, Crizotinib, Complexed renal cyst, Alectinib, Ceritinib
Received: September 27, 2018
Accepted: March 9, 2019
JJLC 59 (3): 260-264, 2019
